Pharmaceutical Treatment For Postpartum Depression Is Fastest Growing Segment Fueling The Growth Of Postpartum Depression Drug Market

Pooja Khodke

Pharmaceutical Treatment For Postpartum Depression Is Fastest Growing Segment Fueling The Growth Of Postpartum Depression Drug Market

The global Postpartum Depression Drug Market is estimated to be valued at Us$ 6.65 Bn in 2023 and is expected to exhibit a CAGR Of 30% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Postpartum depression drug market consists of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and others. These drugs help in restoring imbalances in the levels of chemicals like serotonin and norepinephrine in the brain thereby relieving symptoms such as extreme sadness, anxiety, exhaustion and others associated with postpartum depression.

Market key trends:

One of the major trends in the postpartum depression drug market is the approval and launch of novel drugs for treating postpartum depression. For instance, in 2022, Sage Therapeutics received FDA approval for Zulresso (brexanolone), the first drug specifically approved for treating postpartum depression. Zulresso is administered as a single 60-hour intravenous infusion and works by targeting GABA receptors in the brain to rapidly reduce symptoms of postpartum depression. Such approval and launch of new drugs is expected to drive the market growth during the forecast period.

Segment Analysis:

Selective serotonin reuptake inhibitors (SSRIs) currently dominate the postpartum depression drug market, accounting for over 40% of the overall sales. This is because SSRIs are considered first-line treatment by healthcare professionals for postpartum depression due to their favorable safety and tolerability profiles. Some of the commonly prescribed SSRIs include sertraline (Zoloft), fluoxetine (Prozac), and paroxetine (Paxil). However, the serotonin-norepinephrine reuptake inhibitors (SNRIs) segment is anticipated to experience high growth during the forecast period. SNRIs such as duloxetine (Cymbalta) offer dual reuptake inhibition of both serotonin and norepinephrine, providing more complete antidepressant effects over SSRIs. Additionally, SNRIs may have faster onset of action and better tolerability for some patients.

Key Takeaways:

- The Global Postpartum Depression Drug Market Demand is expected to witness a high growth of 30% over the forecast period, due to rising awareness regarding mental health and increasing diagnosis of postpartum depression.

- North America currently dominates the global market, accounting for over 40% revenue share in 2023. This is attributed to well-established healthcare infrastructure and growing adoption of innovative drugs in the region. However, Asia Pacific region is poised to grow at a highest CAGR during the forecast period driven by increasing affordability of healthcare services and expanding customer base.

- Key players operating in the postpartum depression drug market are Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bayer AG (Germany), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (US), Cipla Inc. (US), Aurobindo Pharma (India), Lupin (India), Accord Healthcare (US), Sun Pharmaceutical Industries Ltd. (India), Bausch Health Companies Inc. (Canada), Alvogen (US), Intas Pharmaceuticals Ltd. (India), SHIONOGI & Co., Ltd. (Japan). Key players are focusing on developing new formulations and expanding regional presence for larger market share.

Get more insights on this topic:

https://www.insightprobing.com/growing-prevalence-of-postpartum-depression-to-boost-growth-of-postpartum-depression-drug-market/

Pooja Khodke

Postpartum Depression Drug Market Is Estimated To Witness High Growth Owing To Opportunity Of Increasing Prevalence Of Postpartum Depression

Poonam 2024-02-05

With rising awareness about postpartum depression and its treatment through effective prescription drugs, the demand for postpartum depression drugs is growing substantially. The global postpartum depression drug market is estimated to be valued at US$ 7. This rising disease prevalence is expected to drive significant demand for postpartum depression drugs over the forecast period. Key Takeaways The global Postpartum Depression Drug Market is expected to witness high growth at a CAGR of 26% during the forecast period of 2024 to 2031. Key players operating in the postpartum depression drug market are Salesforce.

The global Postpartum Depression Drug Market is estimated to be valued at US$ 6.638 Billion In 2022 and is expected to exhibit a CAGR of 30.25%

sachin sadgir 2023-10-26

The global Postpartum Depression Drug Market is estimated to be valued at US$ 6. Several governments and non-profit organizations conduct seminars and awareness programs to educate women and their families about postpartum depression. Here is the segment analysis and key takeaways for the given Postpartum Depression Drug market research report: Segment Analysis The global Postpartum Depression Drug Market is segmented based on drugs, distribution channel, and region. SSRIs are commonly prescribed for postpartum depression as they are considered relatively safe and have fewer side effects compared to other antidepressants. holds the largest market share owing to its innovative drug pipeline for treating postpartum depression.

The Postpartum Depression Drug Market is Estimated to Witness High Growth Owing to the Growing Prevalence of Postpartum Depression

Purvaja 2023-12-28

The global Postpartum Depression Drug Market is estimated to be valued at US$ 6. The increasing awareness and acceptance of postpartum depression as a serious medical condition requiring treatment is encouraging more new mothers to seek help in the form of postpartum depression drugs. This growing acceptance and demand is poised to drive the growth of the postpartum depression drug market over the forecast period. Key Takeaways The Global Postpartum Depression Drug Market is expected to witness high growth over the forecast period of 2023 to 2030. Key players operating in the postpartum depression drug market are Sun Pharma, UCB Farchim SA, Yangtze River Pharmaceutical (Group) Co.

"The Postpartum Depression Drug Market: A Comprehensive Study"

Sumedha 2023-09-28

In this blog post, we will delve into the postpartum depression drug market, exploring its current state and future prospects. Current Market LandscapeThe postpartum depression drug market has seen substantial growth in recent years, driven by an increased awareness of PPD and the need for effective treatments. Challenges and OpportunitiesWhile the postpartum depression drug market has made progress, several challenges persist:1. Future ProspectsThe postpartum depression drug market holds promise for further growth and innovation. ConclusionThe postpartum depression drug market Size has made significant strides in recent years, offering hope to mothers grappling with this challenging condition.

Postpartum Depression Market Size, Share Analysis, Key Companies, and Forecast To 2030

Apeksha Patil 2023-04-03

The Global Postpartum Depression Market Report presents an exhaustive analysis of the Postpartum Depression market and offers investors, stakeholders and business strategists’ valuable insights on the forecast. The global Postpartum Depression market size reached USD 5. The study on the Global Postpartum Depression Market is the latest report covering the impact analysis of the currently ongoing COVID-19 pandemic. The report offers an accurate forecast estimation of the Postpartum Depression industry based on the recent technological and research advancements. It also offers valuable data to assist the investors in formulating strategic business investment plans and capitalize on the emerging growth prospects in the Postpartum Depression market.

Postpartum Depression Management Market Insights, Facts, and Statistics by 2032

Ganesh Shinde 2023-03-10

The global postpartum depression management market is expected to grow at a 3. The postpartum depression (PPD) management market refers to the global market for products and services aimed at diagnosing, treating, and managing PPD, a type of depression that occurs in women after childbirth. 5% of the postpartum depression management market. Because of increased postpartum depression awareness among women, North America has had the greatest revenue share in the worldwide postpartum depression management market over the last decade. Key Players in the Postpartum Depression Management Market:Some of the key players present in the global postpartum depression management market are Sage Therapeutics Inc.

WHO TO FOLLOW